Covidien plc, has announced the European commercial launch of its Nellcor™ Respiration Rate System. In addition to the Adult Respiratory Sensor, the system includes the Nellcor™ Respiration Rate Version 2.0 software and Nellcor™ Bedside Respiratory Patient Monitoring System, PM1000N, both of which recently received CE Mark approval.
Respiration rate is a critical vital sign that can act as an early indicator of respiratory complications.
Covidien’s Nellcor™ Respiration Rate System provides critical information through a continuous, non-invasive patient monitoring platform that enables clinicians to review respiratory trend data over the course of a patient’s treatment. The system is claimed to be accurate – reporting respiration rates of ± 1 breath per minute when compared to respiration rate derived from a capnography-based reference – easy to use, and may enable earlier intervention in the case of respiratory compromise.
With this addition to the Nellcor™ Respiratory Function portfolio – a single-sensor, pleth-based respiration rate monitoring technology – Covidien says clinicians now can monitor a patient’s SpO2, pulse rate and respiration rate through a single integrated finger sensor.
“The methods we currently have available to monitor respiration rate are not always accurate, despite the fact that it is a critical vital sign,” said Dr. Graham Douglas, Respiratory Unit, Aberdeen Royal Infirmary. “The Respiration Rate system from Covidien gives us a better picture of a patient’s overall respiratory status, does not change the workflow of our clinical staff and allows us to better provide effective treatment through a finger sensor that is familiar to clinicians and comfortable for patients.”
“This single integrated sensor technology is a significant development in the patient monitoring industry,” said Matt Anderson, vice president and general manager, Patient Monitoring, Covidien. “It supports Covidien’s goal of being on the forefront of cutting-edge medical technology to enable clinicians to provide better patient care.”
Source: Covidien, plc., Business Wire